Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$6.70 USD
-0.02 (-0.30%)
Updated Aug 6, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ADVM 6.70 -0.02(-0.30%)
Will ADVM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADVM
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
Other News for ADVM
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Truist Financial Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD
Around $88M Bet On NextDecade? Check Out These 3 Stocks Insiders Are Buying
Adverum Biotechnologies announces FDA RMAT designation for Ixo-vec